These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 12559512)

  • 81. [The effect of combined mitoxantrone and methylprednisolone therapy in primary and secondary progressive multiple sclerosis. An applied study in 65 patients].
    Zingler VC; Strupp M; Jahn K; Gross A; Hohlfeld R; Brandt T
    Nervenarzt; 2005 Jun; 76(6):740-7. PubMed ID: 15803287
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Long-term follow-up of pediatric patients treated with mitoxantrone for multiple sclerosis.
    Kornek B; Bernert G; Rostasy K; Mlczoch E; Feucht M; Prayer D; Vass K; Seidl R
    Neuropediatrics; 2011 Feb; 42(1):7-12. PubMed ID: 21557144
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Rituximab for relapsing-remitting multiple sclerosis.
    He D; Zhou H; Han W; Zhang S
    Cochrane Database Syst Rev; 2011 Dec; (12):CD009130. PubMed ID: 22161445
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Cardiac effects of mitoxanthrone therapy in patients with multiple sclerosis.
    Pastuszak Ż; Tomczykiewicz K; Piusińska-Macoch R; Stępień A
    Kardiol Pol; 2016; 74(4):380-4. PubMed ID: 26412472
    [TBL] [Abstract][Full Text] [Related]  

  • 85. T2 lesions and rate of progression of disability in multiple sclerosis.
    Mostert JP; Koch MW; Steen C; Heersema DJ; De Groot JC; De Keyser J
    Eur J Neurol; 2010 Dec; 17(12):1471-5. PubMed ID: 20500805
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Mitoxantrone treatment in patients with early relapsing-remitting multiple sclerosis.
    Cocco E; Marchi P; Sardu C; Russo P; Paolillo A; Mascia M; Solla M; Frau J; Lorefice L; Massole S; Floris G; Marrosu M
    Mult Scler; 2007 Sep; 13(8):975-80. PubMed ID: 17468439
    [TBL] [Abstract][Full Text] [Related]  

  • 87. A randomized crossover study of bee sting therapy for multiple sclerosis.
    Wesselius T; Heersema DJ; Mostert JP; Heerings M; Admiraal-Behloul F; Talebian A; van Buchem MA; De Keyser J
    Neurology; 2005 Dec; 65(11):1764-8. PubMed ID: 16221950
    [TBL] [Abstract][Full Text] [Related]  

  • 88. The Cannabinoid Use in Progressive Inflammatory brain Disease (CUPID) trial: a randomised double-blind placebo-controlled parallel-group multicentre trial and economic evaluation of cannabinoids to slow progression in multiple sclerosis.
    Ball S; Vickery J; Hobart J; Wright D; Green C; Shearer J; Nunn A; Cano MG; MacManus D; Miller D; Mallik S; Zajicek J
    Health Technol Assess; 2015 Feb; 19(12):vii-viii, xxv-xxxi, 1-187. PubMed ID: 25676540
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Autologous hematopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: comparison with secondary progressive multiple sclerosis.
    Casanova B; Jarque I; Gascón F; Hernández-Boluda JC; Pérez-Miralles F; de la Rubia J; Alcalá C; Sanz J; Mallada J; Cervelló A; Navarré A; Carcelén-Gadea M; Boscá I; Gil-Perotin S; Solano C; Sanz MA; Coret F
    Neurol Sci; 2017 Jul; 38(7):1213-1221. PubMed ID: 28396953
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Natalizumab treatment shows low cumulative probabilities of confirmed disability worsening to EDSS milestones in the long-term setting.
    Trojano M; Butzkueven H; Kappos L; Wiendl H; Spelman T; Pellegrini F; Chen Y; Dong Q; Koendgen H; Belachew S;
    Mult Scler Relat Disord; 2018 Aug; 24():11-19. PubMed ID: 29860197
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Spotlight on Interferon-beta-1b in relapsing-remitting and secondary progressive multiple sclerosis.
    McCormack PL; Scott LJ
    BioDrugs; 2004; 18(5):343-7. PubMed ID: 15377176
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Clinical characteristics of responders to interferon therapy for relapsing MS.
    Waubant E; Vukusic S; Gignoux L; Dubief FD; Achiti I; Blanc S; Renoux C; Confavreux C
    Neurology; 2003 Jul; 61(2):184-9. PubMed ID: 12874396
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Laquinimod for multiple sclerosis.
    He D; Han K; Gao X; Dong S; Chu L; Feng Z; Wu S
    Cochrane Database Syst Rev; 2013 Aug; (8):CD010475. PubMed ID: 23922214
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Mitoxantrone: benefits and risks in multiple sclerosis patients.
    Martinelli V; Radaelli M; Straffi L; Rodegher M; Comi G
    Neurol Sci; 2009 Oct; 30 Suppl 2():S167-70. PubMed ID: 19882368
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Mitoxantrone induces natural killer cell maturation in patients with secondary progressive multiple sclerosis.
    Chanvillard C; Millward JM; Lozano M; Hamann I; Paul F; Zipp F; Dörr J; Infante-Duarte C
    PLoS One; 2012; 7(6):e39625. PubMed ID: 22768101
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Evidence Report: The efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.
    Marriott JJ; Miyasaki JM; Gronseth G; O'Connor PW;
    Neurology; 2010 May; 74(18):1463-70. PubMed ID: 20439849
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Combination therapy with mitoxantrone and plasma exchange in aggressive relapsing remitting multiple sclerosis: A preliminary clinical study.
    Tabrizi N; Etemadifar M; Ashtari F; Zahed A; Etemadifar F
    J Res Med Sci; 2012 Sep; 17(9):828-33. PubMed ID: 23826008
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Calcium-phosphate homeostasis in secondary progressive multiple sclerosis patients during mitoxantrone therapy.
    Lis M; Niedziela N; Nowak-Kiczmer M; Kubicka-Bączyk K; Adamczyk-Sowa M
    Neurol Res; 2021 Dec; 43(12):1050-1055. PubMed ID: 34240684
    [TBL] [Abstract][Full Text] [Related]  

  • 99. [Mitoxantrone - an anthraquinone antibiotic with antitumor activity applied for the treatment of multiple sclerosis].
    Szwed M
    Postepy Hig Med Dosw (Online); 2014 Feb; 68():198-208. PubMed ID: 24662788
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Early mitoxantrone-induced cardiotoxicity in secondary progressive multiple sclerosis.
    Paul F; Dörr J; Würfel J; Vogel HP; Zipp F
    BMJ Case Rep; 2009; 2009():. PubMed ID: 21734913
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.